52P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
ANNÉE
2024
AUTEURS
Boige V , Bouche O , Mulot C , Evesque L , Ben Abdelghani M , Phelip JM , Mineur L , Galais MP , Villing AL , Hautefeuille V, de la Fouchardiere C , Genet D , Lassoued S , Carnot A , Mitry E , Jacquot S , Serazin D , Brument E , Winter A , Blons H
CONGRÈS/REVUE
ESMO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES